ARI 2243

Drug Profile

ARI 2243

Alternative Names: ARI-2243

Latest Information Update: 04 Apr 2016

Price : $50

At a glance

  • Originator Arisaph Pharmaceuticals
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 04 Apr 2016 No development reported - Phase-I for Type-2 diabetes mellitus (In volunteers) in USA (PO)
  • 10 Jun 2008 Phase-I clinical trials in Type-2 diabetes mellitus in USA (PO)
  • 10 Jun 2008 Preclinical pharmacodynamics data in Type-2 diabetes presented at the 68th Scientific Sessions of the American Diabetes Association (ADA-2008) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top